11129326

Source:http://linkedlifedata.com/resource/pubmed/id/11129326

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0003250, umls-concept:C0009511, umls-concept:C0205369, umls-concept:C0334227, umls-concept:C0599894
pubmed:issue	10
pubmed:dateCreated	2000-12-20
pubmed:abstractText	The goal of this research is to determine the feasibility of an immunotherapeutic approach based on the use of monoclonal antibodies (mAb) to target complement activation fragments on opsonized cancer cells.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/AR43307
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8605732
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Androgens, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Neoplasm, http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm, http://linkedlifedata.com/resource/pubmed/chemical/Complement C3b, http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin M, http://linkedlifedata.com/resource/pubmed/chemical/Opsonin Proteins
pubmed:status	MEDLINE
pubmed:month	Dec
pubmed:issn	0340-7004
pubmed:author	pubmed-author:BankovichA JAJ, pubmed-author:ChungL WLW, pubmed-author:LindorferM AMA, pubmed-author:NardinAA, pubmed-author:SokoloffM HMH, pubmed-author:SolgaM DMD, pubmed-author:SutherlandW MWM, pubmed-author:TaylorR PRP, pubmed-author:YuanZ LZL
pubmed:issnType	Print
pubmed:volume	49
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	551-62
pubmed:dateRevised	2007-11-14
pubmed:meshHeading	pubmed-meshheading:11129326-Adenocarcinoma, pubmed-meshheading:11129326-Androgens, pubmed-meshheading:11129326-Antibodies, Monoclonal, pubmed-meshheading:11129326-Antibodies, Neoplasm, pubmed-meshheading:11129326-Antibody Specificity, pubmed-meshheading:11129326-Antigens, Neoplasm, pubmed-meshheading:11129326-Bone Marrow Purging, pubmed-meshheading:11129326-Complement C3b, pubmed-meshheading:11129326-Feasibility Studies, pubmed-meshheading:11129326-Flow Cytometry, pubmed-meshheading:11129326-Humans, pubmed-meshheading:11129326-Immunoglobulin M, pubmed-meshheading:11129326-Immunologic Tests, pubmed-meshheading:11129326-Immunomagnetic Separation, pubmed-meshheading:11129326-Immunotherapy, pubmed-meshheading:11129326-Male, pubmed-meshheading:11129326-Neoplasms, Hormone-Dependent, pubmed-meshheading:11129326-Opsonin Proteins, pubmed-meshheading:11129326-Prostatic Neoplasms, pubmed-meshheading:11129326-Rosette Formation, pubmed-meshheading:11129326-Tumor Cells, Cultured
pubmed:year	2000
pubmed:articleTitle	Targeting of cancer cells with monoclonal antibodies specific for C3b(i).
pubmed:affiliation	Department of Urology, University of Virginia School of Medicine, Charlottesville, USA.
pubmed:publicationType	Journal Article, Comparative Study, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't